| Type | Title | Date Released | |
|---|---|---|---|
DEFA14A | Form DEFA14A New | ||
8-K | CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics for Expansion in Institutional Care New | ||
8-K | CorMedix Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position | ||
8-K | CorMedix Announces FDA Acceptance for Priority Review of Supplemental NDA for REZZAYO® for Prophylaxis of Invasive Fungal Diseases | ||
4 | Dillione Janet (Reporting) | ||
4 | Blum Susan (Reporting) | ||
4 | Hurlburt Elizabeth (Reporting) | ||
4 | Zelnick Kaufman Beth (Reporting) | ||
10-Q | Form 10-Q | ||
8-K | CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | ||
8-K | Notice of Proposed Settlement in CorMedix Inc. Derivative Litigation | ||
8-K | CorMedix Inc. Announces Executive Leadership Changes |